In the News
Every year in the United States, approximately 2.1 million children seek medical care for respiratory syncytial virus (RSV). Recently, Pfizer has developed a groundbreaking RSV vaccine specifically designed for infants. The vaccine is administered to expectant mothers during pregnancy, offering protection to their babies. “Most children who contract RSV have mild cold-like symptoms and recover within a week,” said Jill Purdie, M.D., an OBGYN and medical director at Northside Women’s Specialists, part of Pediatrix® Medical Group. “However, some infants — particularly those who were born premature or have an underlying health condition like chronic lung disease or congenital heart disease — develop more serious symptoms.”
View the full story on Health